Login to Your Account

Underreaction, Overreaction

Weighing the Impact: HGSI's Double Dose of Bad News

By Trista Morrison

Monday, April 26, 2010
Human Genome Sciences Inc. got a double dose of bad news last week as partner Novartis AG withdrew its European marketing application for hepatitis C drug Zalbin (albinterferon alfa-2b) and lupus drug Benlysta (belimumab) turned up mixed results in a long-term analysis from a Phase III trial.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription